Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from ZYUS Life Sciences ( (TSE:ZYUS) ).
ZYUS Life Sciences has launched a brokered private placement offering of between C$15 million and C$16 million in units priced at C$0.63, each unit consisting of one common share and half a warrant exercisable at C$0.85, with Canaccord Genuity acting as sole lead agent on a best-efforts, fully marketed basis. The net proceeds are earmarked primarily to advance clinical development of its lead non-opioid pain drug Trichomylin, including completion of a Phase 2a trial and preparation for Phase 2b, positioning the company to progress its pipeline under Canada’s listed issuer financing exemption while providing immediate tradability for new securities, subject to regulatory and TSXV approvals.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Saskatoon-based, clinical-stage life sciences company listed on the TSX Venture Exchange under the symbol ZYUS. The company focuses on developing and commercializing novel non-opioid drug candidates for pain management, with its lead product being Trichomylin softgel capsules, and targets patients seeking alternatives to opioid-based therapies.
Average Trading Volume: 6,214
Technical Sentiment Signal: Sell
Current Market Cap: C$56.05M
See more insights into ZYUS stock on TipRanks’ Stock Analysis page.